Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience

• Adam Suleman,
• Jiajia Liu,
• Lisa K. Hicks,
• Adi Klil Drori,
• Michael Crump,
• Robert Kridel,
• Anca Prica,
• Neil Berinstein

Affiliations

Adam Suleman

Faculty of Medicine, University of Toronto

Jiajia Liu

Faculty of Medicine, University of Toronto

Lisa K. Hicks

Faculty of Medicine, University of Toronto; Division of Medical Oncology and Hematology, St. Michael’s Hospital

Adi Klil Drori

AbbVie, Inc., North Chicago, IL

Michael Crump

Faculty of Medicine, University of Toronto; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre

Robert Kridel

Faculty of Medicine, University of Toronto; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre

Anca Prica

Faculty of Medicine, University of Toronto; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre

Neil Berinstein

Faculty of Medicine, University of Toronto; Sunnybrook Health Sciences Centre, Odette Cancer Centre